IL255079A0 - Methods of treating lung cancer - Google Patents

Methods of treating lung cancer

Info

Publication number
IL255079A0
IL255079A0 IL255079A IL25507917A IL255079A0 IL 255079 A0 IL255079 A0 IL 255079A0 IL 255079 A IL255079 A IL 255079A IL 25507917 A IL25507917 A IL 25507917A IL 255079 A0 IL255079 A0 IL 255079A0
Authority
IL
Israel
Prior art keywords
methods
lung cancer
treating lung
treating
cancer
Prior art date
Application number
IL255079A
Other languages
English (en)
Hebrew (he)
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of IL255079A0 publication Critical patent/IL255079A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL255079A 2015-04-17 2017-10-17 Methods of treating lung cancer IL255079A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (1)

Publication Number Publication Date
IL255079A0 true IL255079A0 (en) 2017-12-31

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255079A IL255079A0 (en) 2015-04-17 2017-10-17 Methods of treating lung cancer

Country Status (13)

Country Link
US (1) US20180125970A1 (enExample)
EP (1) EP3283886B1 (enExample)
JP (1) JP2018516244A (enExample)
KR (1) KR20170137848A (enExample)
CN (1) CN107624071A (enExample)
AU (1) AU2016248222A1 (enExample)
BR (1) BR112017022320A2 (enExample)
CA (1) CA2983126A1 (enExample)
IL (1) IL255079A0 (enExample)
MX (1) MX2017013390A (enExample)
RU (1) RU2718780C9 (enExample)
SG (1) SG11201708546UA (enExample)
WO (1) WO2016168440A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116592A2 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US20170247449A1 (en) * 2014-06-06 2017-08-31 Kyowa Hakko Kirin Co., Ltd Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US11873335B2 (en) 2018-03-13 2024-01-16 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
CA3103369A1 (en) * 2018-06-18 2019-12-26 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
AU2023229967A1 (en) * 2022-03-11 2024-08-08 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716179A2 (en) * 2004-02-12 2006-11-02 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2006116592A2 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
CA2816991C (en) 2010-11-05 2020-06-09 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
EP3330291B1 (en) 2011-07-15 2020-09-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof

Also Published As

Publication number Publication date
JP2018516244A (ja) 2018-06-21
RU2017136863A3 (enExample) 2019-08-21
RU2017136863A (ru) 2019-05-17
SG11201708546UA (en) 2017-11-29
WO2016168440A1 (en) 2016-10-20
CN107624071A (zh) 2018-01-23
RU2718780C2 (ru) 2020-04-14
MX2017013390A (es) 2018-06-13
US20180125970A1 (en) 2018-05-10
RU2718780C9 (ru) 2020-07-08
BR112017022320A2 (pt) 2018-07-24
EP3283886A1 (en) 2018-02-21
AU2016248222A1 (en) 2017-11-09
KR20170137848A (ko) 2017-12-13
EP3283886B1 (en) 2020-01-15
CA2983126A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
IL298497B1 (en) A method for treating cancer
IL323396A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
SG11201708861VA (en) Methods for treating cancer
ZA201804227B (en) Methods of treating cancer
IL255060A0 (en) Combined treatment for cancer
PL3553087T3 (pl) Terapia celowana nowotworu złośliwego płuc
IL253573A0 (en) Combined therapies for the treatment of cancers
SI3377516T1 (sl) Sestavek za zdravljenje raka
IL257691A (en) A method for treating cancer
IL256836B (en) Methods for treating cancer using apilimod
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
IL255022A0 (en) Cancer treatment methods
IL255079A0 (en) Methods of treating lung cancer
IL246558A0 (en) New methods of cancer treatment
IL255018A0 (en) Cancer treatment methods
IL255016A0 (en) Cancer treatment methods
SG10201508795XA (en) Method for treating cancer
HK1262818A1 (en) Methods for treating cancer
HK1262621A1 (en) Methods for treating cancer
AU2015903130A0 (en) Methods for treating tumours